ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.
Revenue (Most Recent Fiscal Year) | $8.12B |
Net Income (Most Recent Fiscal Year) | $612.34M |
PE Ratio (Current Year Earnings Estimate) | 21.49 |
PE Ratio (Trailing 12 Months) | 24.10 |
PEG Ratio (Long Term Growth Estimate) | 1.46 |
Price to Sales Ratio (Trailing 12 Months) | 3.10 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.76 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 15.90 |
Pre-Tax Margin (Trailing 12 Months) | 7.69% |
Net Margin (Trailing 12 Months) | 8.30% |
Return on Equity (Trailing 12 Months) | 11.84% |
Return on Assets (Trailing 12 Months) | 6.25% |
Current Ratio (Most Recent Fiscal Quarter) | 1.21 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.21 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.40 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $112.02 |
Earnings per Share (Most Recent Fiscal Quarter) | $3.38 |
Earnings per Share (Most Recent Fiscal Year) | $12.32 |
Diluted Earnings per Share (Trailing 12 Months) | $8.22 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Diagnostics & Research |
Common Shares Outstanding | 82.50M |
Free Float | 46.20M |
Market Capitalization | $25.53B |
Average Volume (Last 20 Days) | 0.49M |
Beta (Past 60 Months) | 1.15 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 44.00% |
Percentage Held By Institutions (Latest 13F Reports) | 95.61% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |